379 A phase 2, randomized, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics & pharmacogenetics of CC-220 in subjects with SLEV. Werth, Seohee Choi, David Hough et al.|Journal of Investigative Dermatology|2017Cited by 0